Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Saint Louis University is currently managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct art units, which indicates a diverse portfolio with applications covering a wide range of technical sub-fields. The prosecution involves 3 distinct examiners, meaning that each pending matter is being reviewed by a different individual at the patent office. This distribution across 3 distinct art units requires a versatile prosecution strategy.
WHITEMAN, BRIAN A is the busiest examiner for this portfolio, currently handling 1 pending office action. This 1 pending office action is part of the 3 pending office actions currently active for the university. Because the workload is spread across 3 distinct examiners, the prosecution strategy must be adapted to the specific preferences of each individual. Practitioners should be prepared to tailor their arguments to the technical standards of the various art units involved in these cases to achieve successful outcomes.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| GHIMIRE, SHANKAR RAJ | 1 | 76.3% | +19.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001148 | ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES | WILLIS, DOUGLAS M | 37d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001148 | ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES | WILLIS, DOUGLAS M | 37d overdue |
| 18061047 | URINARY CATHETER FOR ENDOSCOPE | GHIMIRE, SHANKAR RAJ | 28d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 3795 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18001148 | ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | 37d overdue | Pending | Dec 08, 2022 |
| 18061047 | URINARY CATHETER FOR ENDOSCOPE | GHIMIRE, SHANKAR RAJ | 3795 | §103 | Final Rejection | 28d | Pending | Dec 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial